Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
about
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewMitochondrial apoptosis and BH3 mimeticsThe potential of venetoclax (ABT-199) in chronic lymphocytic leukemiaPhase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignanciesVenetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia.Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Orphan Nuclear Receptor NR4A1 Binds a Novel Protein Interaction Site on Anti-apoptotic B Cell Lymphoma Gene 2 Family Proteins.MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL.Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation.Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Chronic lymphocytic leukemia: Time to go past genomics?Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells.Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells.Venetoclax is effective in small cell lung cancers with high BCL-2 expression.Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo.The Light and Shadow of Senescence and Inflammation in Cardiovascular Pathology and Regenerative Medicine.Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer.Safety and pharmacodynamics of venetoclax (ABT-199) in a randomized single and multiple ascending dose study in women with systemic lupus erythematosus.Pathways and mechanisms of venetoclax resistance.DMFC (3,5-dimethyl-7H-furo[3,2-g]chromen-7-one) regulates Bim to trigger Bax and Bak activation to suppress drug-resistant human hepatoma.BCL-2 as therapeutic target for hematological malignancies.Bax, Bcl-2, and Bax/Bcl-2 as prognostic markers in acute myeloid leukemia: are we ready for Bcl-2-directed therapy?Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.
P2860
Q27304386-897EF828-15A9-44C7-A5B7-A741800F7FECQ28069552-7BC7B642-BF17-4BC3-95E7-F2302CAE80EAQ28075504-1EB33280-DC27-47E7-A97B-B8A19455E1F3Q33422543-2CFE10B7-C404-4A7A-B640-C297CC3DADF1Q33433407-99D28919-C103-4921-8B55-DEA0A2A45FD2Q34135298-E4EC07ED-80B5-4347-B43E-2B2C0282AE1CQ37035832-6A297DB0-AA4A-459A-8811-C8B79950407EQ37065711-7DAF1F65-CA9A-497C-A04D-1E229FB021F4Q37412499-D26F3A8E-8BFF-4492-BF3E-943FF0E2C32DQ37416797-8DEA3043-385A-41F6-BCA5-967F9F6EC9ACQ37521403-7D378318-DE5A-4E6C-BBF2-69CD7C765C4AQ38193997-33FF5B1B-A2FE-4420-93D4-0AD970D823F2Q38640917-820742F6-3D98-4971-9DF0-C994AF09AAB4Q38708220-46E655AC-2BC1-4CCD-845B-00F116004C6BQ38722012-B8CBCC82-2FE2-4DDC-AACF-D5FBD4F59286Q38756584-5A124A42-D1AF-49D0-B424-23C83E39D3F4Q38779981-1DFA63F7-D09F-47FE-99B0-BB3CD6464F24Q42317487-E4A3E4F1-3C78-4675-874B-EB0A249BAA8AQ45072361-F068F057-9484-4F29-92B0-8A0C5D158362Q45301393-538F3BEC-3A3E-4633-856C-A65874A71B3AQ46305866-25895EE5-451C-497F-82F2-01FFBBA294BBQ47567993-3985F10B-C28B-4542-A811-0DBB8F930874Q48158175-0FF9CDCE-B994-4B17-B4B6-965E51FE41D8Q50575750-4DA3A76C-A351-48CF-8D81-79448ACCF962Q51160342-5C73CC3A-7553-4EB7-8E45-E7A5E43EC788Q51311600-1FEC876E-3A35-46BA-B575-8F40AF53E906Q53684488-81B2A94B-3359-4FA2-9006-3A5507550051Q53702234-A2DDB32E-C88C-4964-9AEB-4E471AA79A9FQ55280895-23593743-1D78-45ED-84DC-37CFC68FF2D3
P2860
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@ast
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@en
type
label
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@ast
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@en
prefLabel
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@ast
Both leukaemic and normal peri ...... rosurvival Bcl-2 with ABT-199.
@en
P2860
P50
P356
P1433
P1476
Both leukaemic and normal peri ...... prosurvival Bcl-2 with ABT-199
@en
P2093
S P Glaser
P2860
P2888
P304
P356
10.1038/LEU.2014.1
P577
2014-01-09T00:00:00Z
P5875
P6179
1048873627